You are here

Article info

Article menu
Download PDFPDF
Editorial
Repositioning compounds from cancer drug discovery to IPF: PI3K inhibition

Authors

  • Claudia A Staab-Weijnitz Comprehensive Pneumology Center, University Hospital, Ludwig-Maximilians-University and Helmholtz Zentrum München, Munich, Germany PubMed articlesGoogle scholar articles
  • Oliver Eickelberg Comprehensive Pneumology Center, University Hospital, Ludwig-Maximilians-University and Helmholtz Zentrum München, Munich, Germany PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Oliver Eickelberg, Comprehensive Pneumology Center, University Hospital, Ludwig-Maximilians-University and Helmholtz Zentrum München, Munich 81377, Germany; oliver.eickelberg{at}helmholtz-muenchen.de
View Full Text

Citation

Staab-Weijnitz CA, Eickelberg O
Repositioning compounds from cancer drug discovery to IPF: PI3K inhibition
Thorax 2016;71:675-676.

Publication history

  • First published June 15, 2016.
Online issue publication 
September 01, 2022

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/